Suppr超能文献

机构临床试验招募与医院容量对头颈部癌症患者生存结局的影响:对 PET-NECK 试验结果、英国临床试验注册网(UKCRN)组合和英格兰医院入院统计(HES)的分析。

The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England.

机构信息

Warwick Clinical Trials Unit, University of Warwick, United Kingdom.

Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, United Kingdom.

出版信息

Oral Oncol. 2018 Oct;85:40-43. doi: 10.1016/j.oraloncology.2018.08.006. Epub 2018 Aug 21.

Abstract

OBJECTIVES

High institutional clinical trial recruitment and high hospital volume are reported to be independent indicators of better patient outcomes following cancer treatment. However, their relationship in head and neck cancers (HNC) remains less clear.

METHODS

We aimed to assess the relationship between institutional clinical trial recruitment, hospital throughput of HNC cases, and survival of patients with advanced HNC treated with primary chemoradiotherapy at hospitals which recruited to the PET-NECK trial (2008-2012). The impact on outcome was assessed using Cox's proportional hazards regression analysis and multivariate analysis.

RESULTS

HNC RCT recruitment positively correlated with hospital throughput (r = 0.57, p < 0.0001). Low-recruiters (1-5 patients) had a 107% increased risk of death when compared to high-recruiters (>5 patients) (HR = 2.07, p = 0.05). There was no significant impact of hospital throughput on overall or disease-specific HNC survival. Multivariate analysis identified p16 status, N-stage, smoking, and RCT recruitment volume as the only significant predictors of survival. There was a significant difference in chemotherapy regimen between low and high-recruiters (p = 0.003) where a higher proportion of patients (50%, n = 13) in low-recruiting compared to high-recruiting hospitals (29%, n = 92) received neoadjuvant chemotherapy. A higher proportion of these patients died at low-recruiting hospitals (46% versus 23%).

DISCUSSION

A significant association exists between high recruitment and better OS for patients with HNC. However, no significance was found between hospital throughput and outcomes. The significance of individual centre differences in chemotherapy regimen needs further investigation. Future studies need a greater number of patient outcome events to support the trends found in this study.

摘要

目的

高机构临床试验招募率和高医院容量被报道为癌症治疗后患者预后更好的独立指标。然而,它们在头颈部癌症(HNC)中的关系仍不太清楚。

方法

我们旨在评估机构临床试验招募、HNC 病例医院吞吐量以及参与 PET-NECK 试验(2008-2012 年)的接受原发放化疗的晚期 HNC 患者生存之间的关系。使用 Cox 比例风险回归分析和多变量分析评估对结果的影响。

结果

HNC RCT 招募与医院吞吐量呈正相关(r=0.57,p<0.0001)。与高招募者(>5 例)相比,低招募者(1-5 例)的死亡风险增加了 107%(HR=2.07,p=0.05)。医院吞吐量对总体或疾病特异性 HNC 生存没有显著影响。多变量分析确定 p16 状态、N 期、吸烟和 RCT 招募量是生存的唯一显著预测因素。低招募者和高招募者之间的化疗方案存在显著差异(p=0.003),低招募者医院(50%,n=13)接受新辅助化疗的患者比例(50%,n=13)高于高招募者医院(29%,n=92)。低招募者医院的死亡比例更高(46%比 23%)。

讨论

高招募与 HNC 患者的 OS 显著相关。然而,医院吞吐量与结果之间没有发现显著相关性。个别中心化疗方案差异的意义需要进一步研究。未来的研究需要更多的患者预后事件来支持本研究中发现的趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验